Keytruda is the first immuno-oncology drug approved to treat first-line lung cancer.
The neurology market is again attracting attention and investment from various — and at times unexpected — corners of the biopharma industry.
Opdivo fails in lung cancer trial; hedge fund sues Theranos; Takeda and Crescendo partner to develop humabody-based therapies
A race has emerged in a new disease space estimated to be worth billions of dollars.
Drugmakers routinely pay ghostwriters to write industry-funded research articles; Horizon to buy Raptor for $800 million; WellDoc partners with J&J
Novartis to fold its cell and gene therapy business; Novo Nordisk CEO to retire; the FDA issues a safety warning for opioids taken with anti-anxiety drugs
You can see it everywhere: on TV and in newspapers and ads. The decades of struggle against cancer are paying off.
Fueled by innovation in new treatments, the underserved women's health market has begun to turn the proverbial corner. What took it so long?
The osteoporosis drug market is bracing for the advent of potentially game-changing treatments.
Only one new osteoporosis drug has been approved over the last six years.
A massive disappointment for Bristol-Myers Squibb's Opdivo in first-line lung cancer has leveled the playfield for Merck's Keytruda.
Opdivo fails to meet endpoint in new lung cancer patients; abuse-deterrent drug gets nod from FDA panel; Cephalon settles pay-for-delay case
Interest in oncology is on the rise as the blockbuster drug era breathes its last, and this has altered marketing in cancer care.
Despite the arrivals of new drugs, Genentech continues to be the market leader. Its drugs, Rituxan, Avastin, and Herceptin, are the category leaders, generating a total of $9.29 billion in sales.
While analysts predict a first-in-class appearance before the FDA by 2018, many obstacles have arisen.
Herceptin biosimilar meets endpoint in clinical trial; Roche plans to launch five new drugs over the next year; government seeks to block insurer deals
Roche's blood cancer drug fails to meet trial goal; the FDA says Valeant's psoriasis drug carries risk of suicide; Facebook tests disappearing messages
GIlead Sciences' new HCV treatment receives approval; FDA adcomm votes in favor of Jardiance health-outcomes' claims; FDA names head of new oncology center
Opdivo nets sixth Breakthrough Therapy designation; AstraZeneca seeks rare indication to block Crestor generics; Endo mulls sale to reduce debt
A trial studying Keytruda met its endpoint in first-line lung cancer patients.
A new Sanofi combination diabetes drug meets clinical trial targets; IBM partners with the American Diabetes Association; Dr. Reddy's to buy eight Teva drugs
Investors said a combination of Opdivo and Yervoy is the top-performing regimen in a niche of non-small cell lung-cancer patients.
Competition among new breast cancer drugs, an immunotherapy contender, and pricing discussions headline one of the biggest cancer conferences of the year.
Drugmakers like Merck are making a big education push as they lay the groundwork for future biosimilars.
The goal is to develop medications that move beyond the high-toxicity and low-efficacy profiles of older drugs.
Opdivo nets new indication; government to view Humira patent; AstraZeneca's asthma drug expected to be filed this year
The bar for market success has been set high for baricitinib.
IMS and Quintiles to merge and create $17 billion firm; Biogen spins off hemophilia company; Google partners with the National Health Service
AstraZeneca to sequence two million genomes; Valeant considering Perrigo CEO as its new chief executive; AMA and PhRMA each spent $6 million on lobbying
Immuno-oncology drugs showing results in hard-to-treat cancers; Express Scripts responds to Anthem lawsuit; BI and Lilly plan outcomes trials for Jardiance
- Sunovion hires former BI exec as VP of marketing
- Five things for pharma marketers to know: Thursday, October 20, 2016
- Five things for pharma marketers to know: Tuesday, October 25, 2016
- Five things for pharma marketers to know: Monday, October 24, 2016
- Five things for pharma marketers to know: Wednesday, October 26, 2016
- Merck educates doctors about biosimilars, long before it will sell one in the U.S.
- 4 trends with the potential to change behavior in the patient journey
- 2016 Pharma Report: All the data in one place
- What do physicians think about biosimilars?
- Novartis considers new sales model for experimental cancer therapy